Axsome starts Phase 3 trial of solriamfetol in children with ADHD

July 7, 2026 7:00 AM

Axsome Therapeutics (NASDAQ: AXSM) announced that the first patient has been dosed in its FOCUS-2 Phase 3 clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found